Clinical trials: Relapsed Leukemia
Acute Lymphocytic Leukemia
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin in patients with refractory or relapsed…
- Trial name
- NCT00271063
- Testing
- Liposomal Annamycin
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Callisto Pharmaceuticals
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
T- cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy) has an increase in proteins in a specific pathway called the mTOR pathway within the cancer cells.
- Trial name
- ENCERT (NCT03328104)
- Testing
- Everolimus, Nelarabine, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based…
- Trial name
- PRODIGY (NCT06227026)
- Testing
- Anti-CD19 CAR-T cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
This project is a prospective, single-center, randomized controlled clinical study. The subjects were high-risk or relapsed/refractory AML or ALL patients aged ≤ 65 years diagnosed by bone marrow cell morphology, immunology…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
- Trial name
- NCT06816134
- Testing
- TmBU conditioning Regimen, mBUCY conditioning regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Myelocytic, Acute
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.
- Trial name
- NCT00126321
- Testing
- cladribine
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bonn
Acute Myeloid Leukemia
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420.
- Trial name
- NCT04580121
- Testing
- RO7283420, Tocilizumab, Dasatinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Leukemia
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003758
- Testing
- cytarabine, idarubicin, allogeneic bone marrow transplantation
- Where
- 16 sites in Belgium, Croatia and 5 more
- Volunteers
- 60 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow…
- Trial name
- NCT00006240
- Testing
- sargramostim, dexamethasone, oral sodium phenylbutyrate
- Where
- 4 sites in United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow…
- Trial name
- NCT04275518
- Testing
- APG-115, Azacitidine, Cytarabine
- Where
- 14 sites in China
- Volunteers
- 102 people
- Sponsor
- Ascentage Pharma Group Inc.
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor [CAR] T cells) in treating patients with acute myeloid leukemia (AML) that has come back after a…
- Trial name
- NCT06871410
- Testing
- Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial studies side effects and best dose of pevonedistat and belinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has come back (relapsed) or does not respond to treatment…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Trial name
- NCT03772925
- Testing
- Belinostat, Pevonedistat
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Lymphoid Malignancies, Multiple Myeloma
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest.
- Conditions
- Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- PDX+Romi (NCT01947140)
- Testing
- Pralatrexate, Romidepsin
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Jennifer Amengual
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT04532268
- Testing
- Humanized CD19 CAR-T cells
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Acute Myeloid Leukemia
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment.
- Trial name
- NCT07306832
- Testing
- Pivekimab Sunirine
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 18 people
- Sponsor
- AbbVie
Leukemia, Myeloid, Acute
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
- Trial name
- NCT00906945
- Testing
- G-CSF, Plerixafor, Mitoxantrone
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
- Trial name
- ZUMA-3 (NCT02614066)
- Testing
- brexucabtagene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 125 people
- Sponsor
- Kite, A Gilead Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.